# The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and Immunogenicity

> **NCT05897008** · PHASE1 · COMPLETED · sponsor: **Taizhou Mabtech Pharmaceutical Co.,Ltd** · enrollment: 114 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** CMAB007
- **BIOLOGICAL:** Xolair

## Key facts

- **NCT ID:** NCT05897008
- **Lead sponsor:** Taizhou Mabtech Pharmaceutical Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-07
- **Primary completion:** 2022-06-27
- **Final completion:** 2022-09-13
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2023-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05897008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05897008, "The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and Immunogenicity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05897008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*